As biotech investors continue to wait for Arena Pharmaceuticals to launch its obesity drug Belviq, pharmaceutical company Vivus (VVUS) has been trying to ramp up sales for its rival drug Qsymia. The company's slow drug launch has been the topic of much debate in past quarters, but it recently reported that its total number of prescriptions shipped in March were 42% greater than scripts in January. Should investors be excited about this result, or will the real catalyst for this stock be its upcoming earnings report for the first quarter of 2013? Health-care analyst Max Macaluso sheds light on this topic in the following video.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Vivus released prescription data for its obesity drug Qsymia last week, but its earnings report is more important.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Our Most Popular Articles
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.